Related Experiment Video
Updated: Oct 18, 2025

06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
13.8K
An Evolving Role for AXL in Metastatic Renal Cell Carcinoma
Andrew W Hahn1, Daniel J George2, Neeraj Agarwal3
1Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract:
High tumoral expression of AXL was associated with inferior response to anti-PD-1 therapy and increased tumoral programmed death ligand 1 (PD-L1) expression in patients with metastatic renal cell carcinoma, with particularly poor outcomes in those with high AXL and PD-L1. AXL expression has potential as a biomarker and therapeutic target.See related article by Terry et al., p. 6749.

